ArticleGenes & development2020
Open access · diamondAbstract read
In one paragraph
Article in Genes & development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Non-coding RNAs' pivotal importance in modulation of cancer sensitivity to Topotecan: a systematic review.Medical oncology (Northwood, London, England) · 2025Pooled it
- YAP1 Defines an Emergent, Plastic Population of Relapsed SCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- FOXA1 drives chemoresistance through activating Wnt pathway in small cell lung cancer.Translational lung cancer research · 2026Article
- Loss of the USP22 deubiquitylase confers resistance to chemotherapy in small cell lung cancer.Nature communications · 2026Article
- KDM4B/DHX9 promotes chemoresistance in small-cell lung cancer through the MYCN-driven signaling pathway.Oncogene · 2026Article
- Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments.Cancer research · 2026Review
- Mitochondrial metabolic-transcriptional axis drives adaptive drug tolerance across major lung cancer subtypes.Frontiers in genetics · 2026Review
- Regulatory roles of five key USP family deubiquitinases in cancer: from mechanisms to targeted therapy advances.Frontiers in pharmacology · 2026Review
- Emerging roles of USP7 in tumor immune evasion, metabolic reprogramming, and therapeutic resistance.Frontiers in immunology · 2026Review
- YAP1 defines an emergent, plastic population of relapsed small cell lung cancer.bioRxiv : the preprint server for biology · 2025Article
- The latest progress of personalized drug screening and therapy research for common clinical tumors through the PDX model platform.Journal of pharmaceutical analysis · 2025Review
- Patient-derived xenograft models: Current status, challenges, and innovations in cancer research.Genes & diseases · 2025Review
- Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Selective targeting of genome amplifications and repeat elements by CRISPR-Cas9 nickases to promote cancer cell death.Nature communications · 2025Article
- In vivo functional screens revealScience advances · 2025Article
- USP9X integrates TGF-β and hypoxia signalings to promote ovarian cancer chemoresistance via HIF-2α-maintained stemness.Cell death & disease · 2025Article
- Current and future therapies for small cell lung carcinoma.Journal of hematology & oncology · 2025Review
- CRISPR/Cas9 system: a novel approach to overcome chemotherapy and radiotherapy resistance in cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Targeting FOXP1 phase separation in small cell lung cancer mechanisms of chemotherapy resistance.Communications biology · 2025Article
- Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?Genes & diseases · 2025Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Eli Grunblatt *Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Nan Wu *Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Huajia ZhangDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Xiaoli LiuDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Justin P NortonDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Yamini OholRAPT Therapeutics, Inc., South San Francisco, California 94080, USA.
Paul LegerRAPT Therapeutics, Inc., South San Francisco, California 94080, USA.
Joseph B HiattDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Emily C EastwoodDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Rhiana ThomasDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Ali H IbrahimDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Deshui JiaDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Ryan BasomGenomics and Bioinformatics Shared Resource, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Keith D EatonDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington 98195, USA.
Renato MartinsDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington 98195, USA.
A McGarry HoughtonDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
David MacPhersonDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Fred Hutch Cancer Center · USUniversity of Washington Medical Center · USAPT Therapeutics (United States) · USRapt Therapeutics (United States) · US
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MUniversity of Washington Medical Scientist Training Program: MD/PhDT32GM007266 · NIGMS · UNIVERSITY OF WASHINGTON · PI HORWITZ, MARSHALL S. · 1985 to 2023
$30.4MTRAINING IN MOLECULAR AND CELLULAR BIOLOGYT32GM007270 · NIGMS · UNIVERSITY OF WASHINGTON · PI RAIBLE, DAVID W · 1985 to 2020
$21.0MProject 4: Risk stratification for pulmonary nodules detected by CT imaging using plasma and imaging biomarkersP50CA228944 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI A McGarry Houghton · 2019 to 2026
$19.6MEmploying CRISPR inactivation screening and in vivo models towards improving treatments for SCLCU01CA235625 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MACPHERSON, DAVID · 2019 to 2023
$2.7MInvestigating CREBBP as a tumor suppressor in small cell lung cancerR01CA200547 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MACPHERSON, DAVID · 2017 to 2021
$2.2MRole of MYC Family Members in Driving Chemoresistance in Small Cell Lung CancerF30CA232475 · NCI · UNIVERSITY OF WASHINGTON · PI GRUNBLATT, ELI · 2018 to 2020
$112kNCI NIH HHS F30 CA232475NCI NIH HHS P30 CA015704NCI NIH HHS P50 CA228944NCI NIH HHS R01 CA200547NCI NIH HHS U01 CA235625NIGMS NIH HHS T32 GM007266NIGMS NIH HHS T32 GM007270
Abstract
Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer characterized by initial chemosensitivity followed by emergence of chemoresistant disease. To study roles for
Indexed as
AnimalsCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmEnzyme ActivationEnzyme InhibitorsHeterograftsHumansLung NeoplasmsMiceN-Myc Proto-Oncogene ProteinSmall Cell Lung CarcinomaUbiquitin-Specific Peptidase 7Enzyme InhibitorsN-Myc Proto-Oncogene ProteinUbiquitin-Specific Peptidase 7chemoresistanceMYCLMYCNSCLCUSP7
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.